Stockscreener 앱 받기
8.86
1.56%
-0.14
시장 영업 전:
8.99
0.13
+1.47%
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
MSN Money - MSN
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Chronicle-Journal
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
BTIG Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
NeoGenomics reports Q1 revenue increase - Gulfshore Business
NeoGenomics Reports First Quarter 2026 Financial Results - HarianBasis.co
Leerink Partners upgrades NeoGenomics (NEO) - MSN
NeoGenomics Earnings Call Highlights NGS-Led Growth - TipRanks
TD Cowen Issues Positive Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock - Stock Titan
Leerink upgrades Neogenomics stock rating on oncology growth outlook By Investing.com - Investing.com Nigeria
NeoGenomics (NASDAQ:NEO) Shares Gap Up Following Analyst Upgrade - MarketBeat
NeoGenomics (NASDAQ:NEO) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Leerink upgrades NeoGenomics to Outperform, raises target to $25 - TipRanks
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 - marketscreener.com
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat - Investing.com UK
Needham reiterates Neogenomics stock Buy rating on strong Q1 beat By Investing.com - Investing.com India
NeoGenomics Shares Jump on Earnings and Analyst Upgrades - Yahoo Finance
Leerink upgrades Neogenomics stock rating on oncology growth outlook - Investing.com
NeoGenomics upgraded to Buy from Hold at Benchmark - TipRanks
NeoGenomics stock surges following earnings, two upgrades By Investing.com - Investing.com South Africa
NeoGenomics stock surges following earnings, two upgrades - Investing.com
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Earnings Call Summary | NeoGenomics(NEO.US) Q1 2026 Earnings Conference - Moomoo
NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth - TradingView
NeoGenomics (NEO) Q1 Loss Of US$17.1 Million Tests Bullish Profitability Narratives - Sahm
NeoGenomics Reports First Quarter 2026 Results - BioSpace
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth By Investing.com - Investing.com Australia
NeoGenomics Q1 2026 Earnings Call Transcript - MarketBeat
NeoGenomics, Inc. Reports Q1 2026 Financial Results and Provides Earnings Highlights - Minichart
NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c - TipRanks
NeoGenomics (NEO) Q1 2026 Earnings Transcript - The Motley Fool
NeoGenomics Q1 Earnings Call Highlights - MarketBeat
NeoGenomics Q1 2026 slides: NGS drives 11% revenue growth - Investing.com
1.63%
0.34%
자본화:
|
볼륨(24시간):